Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation.
Thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation (BMT) is a serious complication that, in contrast to classic TTP, is generally not responsive to therapeutic plasma exchange. We describe the remission of TTP after autologous BMT by administration of cyclosporin in four patients, either after failure of plasmapheresis (two patients) or as primary treatment modality (two patients). Cyclosporin may be an attractive drug for post autologous BMT-TTP.
van Ojik
H
H
Department of Haematology, University Hospital Utrecht, The Netherlands.
Biesma
D H
DH
Fijnheer
R
R
Hené
R J
RJ
Lokhorst
H M
HM
Rooda
S J
SJ
Verdonck
L F
LF
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003524:Cyclosporins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy* / Q000209:etiology
D003524:Cyclosporins